|Videos|February 22, 2019

Do Certain Groups Struggle With PrEP Adherence?

Ian Frank, MD discusses how younger individuals who do not take regular medication may struggle to adhere to the daily routine.

Segment Description: Ian Frank, MD, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses how younger individuals who do not take regular medication may struggle to adhere to the daily routine.

Interview transcript: (modified slightly for readability):

Contagion®: What are some populations in particular that struggle with PrEP adherence?

Frank: I think the people that are most likely to struggle with adherence are young individuals who are not taking any other medication; people who aren't on medication are not in a pill-taking habit. Adolescents, in particular, may not think that they are at risk, and so they may not be as likely to take PrEP on a regular basis.

The studies show that individuals who are engaging in higher-risk behavior — having more frequent sex – are more likely to adhere to the regimens. So, there's an issue with self-perception of risk. Individuals who may not feel what they're doing is risky, may be a little bit less likely to take PrEP.

My advice for individuals who are not adhering, perhaps for that reason, is just to remember that even an individual who has told you that they don't have HIV infection may make that claim on the basis of an HIV test that was done some time ago. And if individuals have had sex after their last HIV test, they could have gotten HIV infected and not know it. So, it's not that they're lying, it's just that they're not aware.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.